Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunct treatment of MDR/XDR tuberculosis with autologous mesenchymal stem cells
DRKS00000763Phase 2Recruiting
- Sponsor
- Republican Research and Practical Center for Pulmonology and Tuberculosis
- Start
- Nov 2011
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous mesenchymal stem cells in Tuberculosis (TB) (2 arms), sponsored by Republican Research and Practical Center for Pulmonology and Tuberculosis. Primary endpoint: Safety and tolerability of autologous mesenchymal stem cell infusion. Started Nov 2011; status: recruiting.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on DRKS00000763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000763.